New hope for tough lung cancer: dual-drug attack shows promise

NCT ID NCT06780137

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests two experimental drugs, MK-6070 and ifinatamab deruxtecan (I-DXd), alone or together, in people with advanced small cell lung cancer that stopped responding to standard treatment. The goal is to see if these combinations can shrink tumors and are safe. About 262 adults will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Aichi Cancer Center ( Site 5000)
RECRUITING

Nagoya, Aichi-ken, 464-8681, Japan
Ankara Bilkent Sehir Hastanesi ( Site 3412)
RECRUITING

Ankara, 06800, Turkey (Türkiye)
Beijing Cancer Hospital ( Site 5401)
RECRUITING

Beijing, Beijing Municipality, 100142, China
Bradfordhill ( Site 2101)
RECRUITING

Santiago, Region M. de Santiago, 8420383, Chile
Cancer Institute Hospital of JFCR ( Site 5002)
RECRUITING

Koto, Tokyo, 135-8550, Japan
Dana Farber Cancer Institute ( Site 1105)
RECRUITING

Boston, Massachusetts, 02215, United States
FALP ( Site 2100)
RECRUITING

Santiago, Region M. de Santiago, 7500921, Chile
Fujian Cancer Hospital ( Site 5413)
RECRUITING

Fuzhou, Fujian, 350014, China
HOSPITAL CLÍNIC DE BARCELONA ( Site 3310)
RECRUITING

Eixample, Barcelona, 08036, Spain
Hacettepe Universite Hastaneleri ( Site 3410)
RECRUITING

Ankara, 06230, Turkey (Türkiye)
Hospital Clinico San Carlos... ( Site 3316)
RECRUITING

Madrid, Madrid, Comunidad de, 28040, Spain
Hospital Universitari Vall d'Hebron ( Site 3311)
RECRUITING

Barcelona, 08035, Spain
Hospital Universitario Austral ( Site 2204)
RECRUITING

Pilar, Buenos Aires, B1629WWA, Argentina
Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 3315)
RECRUITING

Madrid, 28040, Spain
Hospital Universitario HM Sanchinarro ( Site 3313)
RECRUITING

Madrid, 28050, Spain
Hospital Universitario Virgen de la Victoria ( Site 3312)
RECRUITING

Málaga, 29010, Spain
Institut Català d'Oncologia - L'Hospitalet ( Site 3317)
RECRUITING

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1103)
RECRUITING

Hackensack, New Jersey, 07601, United States
Kansai Medical University Hospital ( Site 5004)
RECRUITING

Hirakata, Osaka, 573-1191, Japan
Medical College of Wisconsin ( Site 1112)
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Monash Health ( Site 5301)
RECRUITING

Clayton, Victoria, 3168, Australia
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology ( Site 5403)
RECRUITING

Nanjing, Jiangsu, 210008, China
National Cancer Center Hospital East ( Site 5001)
RECRUITING

Kashiwa, Chiba, 277-0882, Japan
National Cheng Kung University Hospital ( Site 5202)
RECRUITING

Tainan, 704, Taiwan
National Institute for Health Research UCLH Clinical Research Facility ( Site 3902)
RECRUITING

London, London, City of, W1T 7HA, United Kingdom
Pontificia Universidad Catolica de Chile ( Site 2102)
RECRUITING

Santiago, Region M. de Santiago, 8330032, Chile
Princess Alexandra Hospital ( Site 5300)
RECRUITING

Woolloongabba, Queensland, 4102, Australia
Providence Portland Medical Center ( Site 1101)
RECRUITING

Portland, Oregon, 97213, United States
Rabin Medical Center ( Site 3203)
RECRUITING

Petah Tikva, 4941492, Israel
Rambam Health Care Campus ( Site 3202)
ACTIVE_NOT_RECRUITING

Haifa, 3109601, Israel
Roswell Park Cancer Institute ( Site 1107)
RECRUITING

Buffalo, New York, 14263, United States
Samsung Medical Center ( Site 5101)
RECRUITING

Seoul, 06351, South Korea
Sanatorio Parque ( Site 2203)
RECRUITING

Rosario, Santa Fe Province, S2000DSV, Argentina
Sarah Cannon Research Institute ( Site 7001)
RECRUITING

Nashville, Tennessee, 37203, United States
Seoul National University Hospital ( Site 5100)
RECRUITING

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System ( Site 5102)
RECRUITING

Seoul, 03722, South Korea
Shaare Zedek Medical Center ( Site 3200)
RECRUITING

Jerusalem, 9103102, Israel
Shanghai Chest Hospital ( Site 5400)
RECRUITING

Shanghai, Shanghai Municipality, 200030, China
Shanghai Pulmonary Hospital ( Site 5405)
RECRUITING

Shanghai, Shanghai Municipality, 200433, China
Sheba Medical Center ( Site 3201)
RECRUITING

Ramat Gan, 5265601, Israel
Taipei Medical University Hospital ( Site 5201)
RECRUITING

Taipei, 11030, Taiwan
The Christie NHS Foundation Trust ( Site 3901)
RECRUITING

Manchester, M20 4BX, United Kingdom
The Clatterbridge Cancer Centre ( Site 3903)
RECRUITING

Liverpool, L7 8YA, United Kingdom
The First Affiliated Hospital, Zhejiang University ( Site 5404)
RECRUITING

Hangzhou, Zhejiang, 310000, China
University of Chicago ( Site 1108)
RECRUITING

Chicago, Illinois, 60637, United States
University of Colorado Anschutz Medical Campus ( Site 1110)
RECRUITING

Aurora, Colorado, 80045, United States
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1111)
RECRUITING

Miami, Florida, 33136, United States
West China Hospital of Sichuan University ( Site 5416)
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.